AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more

Plus: Data from Innovent, Agenus, Merck, Bayer and Orion

BioCentury’s roundup of translational innovations

Plus: Obesity play Carmot seeking NASDAQ IPO and updates from AZ, Astellas, Merck and Lilly

CHMP’s November opinions include four new medicines and an expansion of Mounjaro’s label to include obesity

Plus: EC fines Illumina over Grail takeout and updates from Novartis, EMA, Arthrosi, newco Raya and  

Plus: Simcere grows Massachusetts presence, and updates from Eisai, Bliss, Eccogene, Phathom, Ironwood and more

BioCentury’s 31st annual Buyside View finds that despite the extended downturn, investors see plenty of milestones to drive excitement this year